

Bartter syndrome – report of an unusual late presentation case and brief review

Síndrome de Bartter – um caso raro de apresentação tardia, e breve revisão

Bernardo M Costa, Joaquim Calado, David Navarro, Fernando Nolasco

Department of Nephrology, Renal Transplantation Unit, Hospital Garcia de Orta, Almada, Portugal.

Received for publication: 27/09/2015

Accepted in revised form: 11/11/2015

■ ABSTRACT

Bartter syndrome is a rare autosomal recessive condition caused by the inability of the thick ascending limb to reabsorb filtered sodium and chloride. Types I and II, called *antenatal Bartter syndrome*, are the most severe, and manifest *in-utero* as polyhydramnios, preterm labour, salt wasting, life-threatening volume depletion, and severe hypokalemic metabolic alkalosis, with a high early mortality rate if untreated. Type III is called *classic Bartter syndrome* and is usually milder and often diagnosed later, in early adolescence. Type IV is as severe as types I and II, but courses with sensorineural deafness. Type V is the latest entry to the Bartter-like syndromes. The defective transporter proteins responsible for these subtypes have been identified and their mutations have been characterized using genetic sequencing and *in vitro* heterologous expression models.

We present an unusual case of a very late diagnosis of an attenuated type IV Bartter syndrome. Our suspicion of the G47R mutation in the β -subunit (Barttin) of the ClC-K chloride channels was confirmed by genetic sequencing. This is a second unrelated case in our centre. Although there is significant variability in the presentation of some subtypes of Bartter syndrome, there is still a strong genotype-phenotype correlation in some mutations, like the one we present here. The acknowledgement of this has provided insight into the genetic and molecular mechanisms of the disease.

Key-Words: Bartter syndrome; Bartter syndrome, type 4A; BSND protein, human; hypokalemia; mutation; renal tubular transport, inborn errors.

RESUMO

O síndrome de Bartter é uma doença autossómica recessiva rara, causada pela incapacidade da segmento ascendente da ansa de Henle de reabsorver o cloro e sódio filtrados. Os tipos I e II, chamados *síndrome de Bartter pré-natal*, são os mais graves. Manifestam-se *in-utero* por polihidrâmnios, parto prematuro, perda urinária de sal, contração de volume, e hipocaliémia grave com alcalose metabólica, apresentando uma elevada mortalidade precoce se não tratado. O tipo III é chamado *síndrome de Bartter clássico*, tipicamente é menos grave e só é diagnosticado frequentemente na adolescência. O tipo IV é tão grave como os tipos I e II, mas é acompanhado de surdez neurosensitiva. O tipo V foi o último a juntar-se aos síndromes “Bartter-like”. As proteínas transportadoras não-funcionantes responsáveis pelos vários subtipos já foram identificadas e as suas mutações caracterizadas, graças à sequenciação genética, e a modelos de expressão heteróloga *in vitro*.

Apresentamos um caso raro de diagnóstico tardio de Síndrome de Bartter tipo IV. A suspeita de estarmos perante a mutação G47R na subunidade β (Barttina) dos canais de cloro CIC-K foi confirmada por sequenciação genética. Este é o segundo caso no nosso centro (não-aparentados). Apesar de haver uma variabilidade significativa na apresentação de alguns subtipos de síndrome de Bartter, existem fortes correlações genotipo-fenotipo em algumas mutações, como a que apresentamos aqui. A constatação deste facto tem proporcionado o aumento do nosso conhecimento sobre os mecanismos genéticos e moleculares desta doença.

Palavras-Chave: Erros congénitos; mutação; hipocaliémia; proteína BSND, humana; síndrome de Bartter; síndrome de Bartter, tipo A4; transporte nos túbulos renais.

INTRODUCTION


The healthy glomerulus filters large volumes of blood through a barrier that is semipermeable to molecules, depending on their size and electric charge. Very small molecules like water and electrolytes are filtered easily and enter the renal tubules in massive amounts that must be reabsorbed in order to maintain homeostasis. Bartter syndrome (BS), first described in 1962, is one of the hereditary salt-wasting tubulopathies which have been increasingly better characterized over the past 20 years through the identification of the malfunctioning transmembrane transporters and the mutations responsible for those defects¹.

Bartter syndrome is a rare condition caused by the inability of the thick ascending limb (TAL) to actively reabsorb filtered sodium and chloride. This can be caused by the malfunctioning of any of four interdependent gene products (Fig. 1), namely: 1) the apical furosemide-sensitive Na-2Cl-K cotransporter (NKCC2) encoded by the *SLC12A1* gene^{2,3}; 2) the apical potassium ROMK channel (*KCNJ1* gene)⁴; 3) the basolateral chloride channel CIC-Kb (*CLCNKB* gene)⁵; and 4) the chloride channels' β -subunit Barttin (*BSND* gene) necessary for the activation of both CIC-Kb and

CIC-Ka⁶. Inactivating mutations in any of these genes produce the different subtypes of Bartter syndrome (types I, II, III, and IV respectively), which are all autosomal recessive. Additionally, other molecules, like the basolateral calcium-sensing receptor (CASR) and the intracellular signalling protein WNK can modulate

Figure 1

Tubular transport of electrolytes at the thick ascending limb.



Abbreviations: CLCKA and CLCKB, renal chloride channels; NKCC2, Na⁺-K⁺-2Cl⁻ cotransporter; ROMK, renal outer medullary potassium channel. Reprinted by permission from the Macmillan Publishers Ltd: Nature Clinical Practice Nephrology, 2008².

the expression of these transporters, and produce Bartter-like syndromes⁷. The constitutional activation of CASR inhibits the activity of NKCC2 and is now called BS type V⁸.

Other conditions that induce extra-renal chloride and volume losses with similar metabolic abnormalities are sometimes called Pseudo-Bartter syndromes. Examples of this are cystic fibrosis, abuse of laxatives and bulimia, all of which can be easily ruled out with a low urinary chloride measurement. Surreptitious diuretic use, on the other hand, can only be ruled out by careful interrogation of the patient or a positive urinary drug test⁹.

Phenotypically, the four subtypes of Bartter syndrome manifest differently. Types I and II constitute what is termed *antenatal Bartter syndrome* (sometimes called hyperprostaglandin E2 syndrome, because high urinary prostaglandin levels were used for its diagnosis). They are the most severe. They manifest first *in-utero* with polyhydramnios, and infants exhibit polyuric hypostenuria, life-threatening volume depletion, low blood pressure, impaired development and high early mortality if left untreated. Some, but not all, develop renal failure. Types I and II also exhibit hypercalciuria and nephrocalcinosis, since the paracellular reabsorption of calcium and magnesium depends on the secretion of potassium to the lumen, in order to create a favourable electrochemical gradient¹⁰. Type III is termed *classical Bartter syndrome*. Usually it is clinically milder (due to partial compensation by the functioning ClC-Ka chloride channel), manifests in early adolescence, and may mimic Gitelman syndrome, including its characteristic hypomagnesaemia and hypocalciuria¹¹. It should be noted though that Bartter syndrome type III is highly variable, and severe cases have been reported. Type IV is called *antenatal Bartter syndrome with sensorineural deafness*. Its presentation is similar to that of types I and II, with the addition of a hearing deficit. This is because both chloride channels are expressed and have a functional role at the inner ear epithelium¹².

Common to all types of BS, patients exhibit hyperreninemic hyperaldosteronism secondary to volume depletion. This induces a persistent hypokalaemic metabolic alkalosis due to the distal tubule effects of aldosterone, which increases distal sodium absorption at the expense of increased K⁺ and H⁺ secretion. Another common finding is overproduction of

prostaglandin E2, as a consequence of salt wasting, which further reduces sodium chloride absorption at the TAL. This is the reason why inhibitors of cyclooxygenase like indomethacin have long been used in the treatment of severe cases.

Although there is significant variability in the presentation of some subtypes of BS, there is still a strong genotype-phenotype correlation in some mutations, like the one we present in the following case.

CASE REPORT

We present a patient first referred to us at the age of 59. His parents were 2nd degree cousins. The gestation period was unremarkable aside from mild polyhydramnios. He was congenitally deaf, had minor cognitive and motor impairment, epilepsy and bilateral inguinal hernias. He was referred to us for the evaluation of persistent hypokalaemia and low blood pressure, which were being treated with oral KCl supplementation (24 mEq/day) and etilefrine. Relevant serum and urinary biochemical data are summarized in (Table I). Blood tests

Table I

Laboratory biochemical results at presentation.

		Normal range
Blood		
pH	7.50	7.35-7.45
HCO ₃ (mEq/L)	36	22-26
paCO ₂ (mmHg)	47	35-45
K ⁺ (mEq/L)	2.4	3.5-5.1
Na ⁺ (mEq/L)	135	136-145
Cl ⁻ (mEq/L)	86	98-106
Mg ²⁺ (mg/dL)	2.25	1.8-2.6
Ca ²⁺ (mg/dL)	9.7	8.8-10.8
BUN (mg/dL)	41	18-55
Creatinine (mg/dL)	1.0	0.67-1.17
Measured CrCl (mL/min)	137	90-139
Aldosterone (ng/dL)	85	1-31
Renin (ng/mL)	212	< 27.8
Urine		
Urine output (mL/24h)	4950	600-1800
Creatinine (mg/24h)	1683	1040-2350
Na ⁺ (mEq/24h)	243	40-220
K ⁺ (mEq/24h)	130	25-125
Cl ⁻ (mEq/24h)	262	110-250
Ca ²⁺ (mg/24h)	181	100-320
Mg ²⁺ (mg/24h)	100	73-122

showed hyperreninaemic hyperaldosteronism with metabolic alkalosis, hypokalaemia and hypochloremia. Serum magnesium level was normal. The 24h urine collection showed hypernatruria, hyperkaliuria, and hyperchloriguria. Urinary calcium levels were normal. BUN, creatinine and measured creatinine clearance were normal. Nephrocalcinosis was evident in the ultrasound and plain abdominal radiograph (Fig. 2). In spite of the patient's age, the metabolic derangements and hearing impairment led us to consider Bartter syndrome type IV. Genetic testing confirmed homozygotic substitution of c.139G>A in the *BSND* gene resulting in Gly to Arg at position 47 (p.G47R) (Fig. 3).

The oral KCl supplementation was increased to 72 mEq/day, with significant improvement of the hypokalaemia (3.3 mEq/L; reference 3.5-5.0 mEq/L) and no further therapeutic interventions were considered necessary.

Figure 2

Nephrocalcinosis on ultrasound scan.





Figure 3

Homozygotic substitution of c.139G>A, resulting in Gly>Arg (p.G47R).



DISCUSSION

From our review of the literature, we have identified 10 published cases of late onset attenuated Bartter syndrome type IV due to the G47R mutation, 1 of them from our centre¹³⁻¹⁶. The patient we present here is unrelated to the previous one and, to the best of our knowledge, this is the oldest patient at the time of diagnosis.

Most of the clinical features and biochemical results presented in this case are in accordance with the previously published cases. The most intriguing aspect of this case is the absence of hypercalciuria, given the presence of frank nephrocalcinosis. This has already been described in a patient with unexplained reduced glomerular filtration rate, and it was speculated that as the renal insufficiency progressed, the lower filtered calcium load would be effectively handled by alternative calcium channels, and any hypercalciuria that might have been present initially, would afterwards subside¹⁵. In our past case, glomerular filtration was normal, and hypercalciuria was persistent, which is compatible with this hypothesis. Conversely, in the present case we did not find hypercalciuria even though the creatinine clearance was normal. This suggests that either other mechanisms that account for the resolution of the hypercalciuria are in place, or that nephrocalcinosis is dependent on other factors besides the increased calcium loss. A possible example of this is hypocitraturia. Garcia-Nieto *et al.* found hypocitraturia in 4 out of the 5 cases of G47R variant of BS-IV they reported on, including one with nephrocalcinosis, normal creatinine clearance and no hypercalciuria¹³. Unfortunately, due to the small number of reported cases, the other factors involved in the calcification process in this rare phenotype have not been characterized.

Another interesting aspect of this case is the good response to oral KCl supplementation alone. The treatment of more severe Bartter syndrome cases usually requires the addition of a non-steroidal anti-inflammatory drug (NSAID) (in order to decrease prostaglandin production and reduce the filtration rate, water, and salt wasting) and sometimes a potassium sparing diuretic (spironolactone or amiloride). However, these medications carry a risk of chronic renal toxicity, gastrointestinal and cardiovascular adverse events, volume depletion and severe electrolyte disturbances¹¹. Since the G47R variant of BS-IV allows for some residual function of ClC-K channels, it is probable that the potassium wasting is less severe

and, hence, the response to supplementation is better than that of more severe phenotypes. In our small experience (2 cases), potassium supplementation was enough. Once more, due to the small number of cases and unreported results of the therapeutic interventions there is not enough data to make confident statements about the treatment of this variant.

We believe that these cases are relevant because they allow us to create strong clinical-to-molecular correlations. When this BSND mutation and its unusual presentation were first identified, it was speculated that it might originate a protein that retained some residual function, which would explain its milder phenotype. Using confocal microscopy and an *in vitro* model with heterologous expression of disease-causing mutations of the *BSND* gene in MCKD cells, Jansen GH *et al.* showed how three missense mutations and two nonsense mutations originate non-functioning proteins. This was because the mutated Barttin protein would either not allow the migration and insertion of the channel in the basolateral membrane, or its activation, or both. Another missense mutation that they studied was the G47R, which produces a mutant Barttin that binds weakly to ClC-K chloride channels, leaving large amounts of the unbound channel wandering in the cytoplasm, and significantly reducing the chloride conductance of the cells¹⁷.

Nevertheless, the same mutation may originate significantly different phenotypes, which is especially evident in BS type III. It has been speculated that this may be because of individual variability in the genes of additional channels and transporters (like the ClC-Ka, the NaCl cotransporter, or the CFTR), or because of variability in modifying genes that regulate expression¹⁸. Interestingly, one case of antenatal Bartter syndrome with sensorineural deafness without a mutated *BSND* gene has been reported, where the researchers cleverly deduced and subsequently demonstrated that both ClC-Kb and ClC-Ka had simultaneous inactivating mutations¹⁹. This has been classified as BS type IVB, as opposed to BS type IVA, which is due to mutations in Barttin.

In conclusion, Bartter syndrome is a fascinating genetic disorder that has greatly improved our understanding on the mechanisms of renal tubular solute transport and its genetic foundations, which despite our great advances, continues to pose a diagnostic challenge both at the consultation room and at the laboratory.

Conflict of Interest statement: None to declare.

References

1. Bartter FC, Pronove P, Gill JR, MacCardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. *Am J Med* 1962; 33:811–828.
2. Naderi AS, Reilly RF Jr. Hereditary etiologies of hypomagnesemia. *Nat Clin Pract Nephrol* 2008;4(2):80–89.
3. Simon DB1, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. *Nat Genet* 1996 Jun;13(2):183–188.
4. Simon DB, Karet FE, Rodríguez-Soriano J, *et al.* Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. *Nat Genet* 1996;14(2):152–156.
5. Simon DB, Bindra RS, Mansfield TA, *et al.* Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. *Nat Genet* 1997;17(2):171–178.
6. Birkenhäger R, Otto E, Schürmann MJ, *et al.* Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. *Nat Genet* 2001; 29(3):310–314.
7. Kleta R, Bockenhauer D. Bartter syndromes and other salt-losing tubulopathies. *Nephron Physiol* 2006;104(2):73–80.
8. Vargas-Poussou R, Huang C, Hulin P, *et al.* Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. *J Am Soc Nephrol* 2002;13(9):2259–2266.
9. Amirlak I, Dawson KP. Bartter syndrome: an overview. *QJM* 2000; 93(4):207–215.
10. Kurtz I. Molecular pathogenesis of Bartter and Gitelman's syndromes. *Kidney Int* 1998;54(4):1396–1410.
11. Seyberth HW. An improved terminology and classification of Bartter-like syndromes. *Nat Clin Pract Nephrol* 2008;4(10):560–567.
12. Estévez R, Boettger T, Stein V, *et al.* Barttin is a Cl- channel beta-subunit crucial for renal Cl- reabsorption and inner ear K+ secretion. *Nature* 2001; 414(6863):558–561.
13. Garcia-Nieto V, Flores C, Luis-Yanes MI, Gallego E, Villar J, Claverie-Martín F. Mutation G47R in the BSND gene causes Bartter syndrome with deafness in two Spanish families. *Pediatr Nephrol* 2006; 21(5):643–648.
14. Brum S, Rueff J, Santos JR, Calado J. Unusual adult-onset manifestation of an attenuated Bartter syndrome type IV renal phenotype caused by a mutation in BSND. *Nephrol Dial Transplant* 2007;22(1): 288–289.
15. Miyamura N, Matsumoto K, Taguchi T, *et al.* Atypical Bartter syndrome with sensorineural deafness with G47R mutation of the beta-subunit for ClC-Ka and ClC-Kb chloride channels, barttin. *J Clin Endocrinol Metab* 2003;88(2):781–786.
16. Park CW, Lim JH, Youn DY, *et al.* Renal dysfunction and barttin expression in Bartter syndrome Type IV associated with a G47R mutation in BSND in a family. *Clin Nephrol* 2011;75 (Suppl 1):69–74.
17. Janssen AG, Scholl U, Domeyer C, Nothmann D, Leinenweber A, Fahlke C. Disease-causing dysfunctions of barttin in Bartter syndrome type IV. *Am Soc Nephrol* 2009;20(1): 145–153.
18. Konrad M, Vollmer M, Lemmink HH, *et al.* Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. *J Am Soc Nephrol* 2000;11(8):1449–1459.
19. Schlingmann KP, Konrad M, Jeck N, *et al.* Salt wasting and deafness resulting from mutations in two chloride channels. *N Engl J Med* 2004;350(13):1314–1319.

Correspondence to:

Dr. Bernardo Costa
Department of Nephrology, Hospital Curry Cabral – Centro Hospitalar Lisboa Central, EPE,
Rua da Beneficência, nº 8, 1069-166 Lisbon, Portugal.
E-mail: bmarquesdacosta@gmail.com